Abstract: The present invention relates to a compound for use as a medicament in the treatment or prevention of acute liver failure, which acute liver failure is induced by intoxication prior to or following administration of the compound. Accordingly, the invention relates to the compound for use in the treatment of an intoxication that without treatment is expected to result in acute liver failure or that without treatment is sufficient to induce acute liver failure. The invention also provides the compound for use in the treatment, and a corresponding method for the treatment of an intoxication sufficient to induce acute liver failure.

Abstract: The present invention relates to a compound for use as a medicament in the treatment or prevention of acute liver failure, which acute liver failure is induced by intoxication prior to or following administration of the compound. Accordingly, the invention relates to the compound for use in the treatment of an intoxication that without treatment is expected to result in acute liver failure or that without treatment is sufficient to induce acute liver failure. The invention also provides the compound for use in the treatment, and a corresponding method for the treatment of an intoxication sufficient to induce acute liver failure.

Abstract: Small inhibitory RNA (siRNA) molecules, which e.g. are purified and/or isolated, as an active in a medicament, which siRNA molecules are inhibitory RNA molecules that through RNA interference (RNAi) reduce or prevent expression of the p53 upregulated modulator of apoptosis (PUMA). The siRNA molecules can be administered as a medicament to a patient suffering from an impaired liver function or from liver damage for the treatment of a functionally impaired liver, for delaying a deterioration of liver function and/or for prevention of liver failure, especially in patients who suffer from a critical impairment of damage to the liver, e.g. for delaying the complete failure of liver function.